Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label fixed-dose RHB-104 study in Crohn's disease
2016-005199-90Phase 3Terminated
- Sponsor
- RedHill Biopharma
- Start
- Feb 2018
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clarithromycin, rifabutin, clofazimine in Crohn's disease, sponsored by RedHill Biopharma. Started Feb 2018; status: terminated.
02
Drugs
clarithromycinrifabutinclofazimine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-005199-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005199-90.